Matthew Biegler
Analyst
Oppenheimer
Equibles does not estimate personal net worth.
About Matthew Biegler
Matthew Biegler is recorded as Analyst at Oppenheimer. Matthew Biegler has spoken on 2 earnings calls across 2 companies, most recently for Fulcrum Therapeutics, Inc. on April 27, 2026. Those appearances were for Fulcrum Therapeutics, Inc. (FULC) and CytomX Therapeutics, Inc. (CTMX). The companies whose calls Matthew Biegler spoke on are classified in the Healthcare sector.
Matthew Biegler on recent calls
“Maybe just piggybacking on some of the earlier comment that you made, Alex, I'm thinking about maybe potential future combination strategies here. And, you know, you mentioned PKR activators and some of the other quote-unquote downstream treatments where you guys are more upstream and maybe that makes logical sense.”
“Could you comment on positioning relative to the other ADCs in development, like Presum TCT, especially now with diarrheal prophylaxis seeming to work well? What are, like, the puts and takes from a physician's perspective in choosing one of the ADCs over the other?”
Affiliation history
-
Oppenheimer
Analyst
Transcript header (unverified)
Current